{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:55:06Z","timestamp":1787025306085,"version":"build-2736575974"},"reference-count":77,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Eosinophils have a double-edged role in the human body, being essential in important physiologic functions but whose presence is conspicuous in a variety of diseases characterized by a T2 inflammation phenotype. Eosinophils are exquisitely sensitive to corticosteroids,\n and the latter have, until recently, represented the cornerstone of treatment of eosinophilic diseases. However, most patients remain dependent on oral corticosteroids, with a notable adverse effect burden and experience a chronic relapsing disease that leads to high morbidity and mortality.\n Treatment prospects have changed with the advent of biologic drugs that target the eosinotropic cytokine interleukin (IL) 5 or its receptor. The success of the latter drugs in severe eosinophilic asthma has paved the way for their use in other, rarer, eosinophilic lung diseases. Recently,\n mepolizumab, a humanized monoclonal antibody that works against IL-5, was approved for the add-on treatment of relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA) in patients ages \u2265 6 years. Benralizumab, a humanized antibody that binds to the \u03b1\n portion of the IL-5 receptor, is also being tested for its efficacy in EGPA in two clinical trials, after a growing number of case reports and case series supported its use as a steroid-sparing agent in the treatment of EGPA.\n                    <jats:bold>Methods:<\/jats:bold>\n                    In this review, we summarized the scientific\n literature evaluating the efficacy of benralizumab treatment in patients afflicted with rare primary eosinophilic lung diseases.\n                    <jats:bold>Results:<\/jats:bold>\n                    The literature we found, largely case reports, reported that the use of benralizumab in EGPA, chronic eosinophilic pneumonia (CEP) and\n allergic bronchopulmonary aspergillosis (ABPA) often led to a depletion of eosinophils, less exacerbations and a decreased systemic corticosteroid burden. No adverse effects were reported.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Benralizumab has a prospective role in the treatment of rare eosinophilic\n lung diseases, which needs to be further elucidated in randomized controlled trials.\n                  <\/jats:p>","DOI":"10.2500\/aap.2022.43.220056","type":"journal-article","created":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:30:51Z","timestamp":1667694651000},"page":"494-500","source":"Crossref","is-referenced-by-count":5,"title":["Benralizumab in the management of rare primary eosinophilic lung diseases"],"prefix":"10.2500","volume":"43","author":[{"given":"Daniel","family":"Griscti Soler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bennici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.chest.2019.04.101","article-title":"Group 2 innate lymphoid cells in airway diseases","volume":"156","author":"Kato","year":"2019","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jaci.2007.03.043","article-title":"Eosinophils: singularly destructive effector cells or purveyors of immunoregulation?","volume":"119","author":"Jacobsen","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1248\/bpb.b19-00095","article-title":"Steroid-resistant asthma and neutrophils","volume":"43","author":"Nabe","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"B6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2014.00549","article-title":"Eosinophilic granulomatosis with polyangiitis: an overview","volume":"5","author":"Gioffredi","year":"2014","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"104036","DOI":"10.1016\/j.lpm.2020.104036","article-title":"Updates for the treatment of EGPA","volume":"49","author":"Raffray","year":"2020","journal-title":"Presse Med"},{"key":"B8","first-page":"100830","article-title":"P-ANCA negative eosinophilic granulomatosis with polyangiitis","volume":"27","author":"Ullah","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"B9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12931-021-01775-z","article-title":"Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series","volume":"22","author":"Detoraki","year":"2021","journal-title":"Respir Res"},{"key":"B10","article-title":"FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome"},{"key":"B11","article-title":"New add-on treatment for rare autoimmune inflammatory disorder | European Medicines Agency [Internet]"},{"key":"B12","doi-asserted-by":"crossref","first-page":"858344","DOI":"10.3389\/fphar.2022.858344","article-title":"Case report: severe eosinophilic asthma associated with ANCA-negative EGPA in a young adult successfully treated with benralizumab","volume":"13","author":"Ricciardi","year":"2022","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.anai.2020.05.002","article-title":"Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab","volume":"125","author":"Chica-Guzm\u00e1n","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.medcli.2021.07.017","article-title":"Benralizumab in eosinophilic granulomatosis with polyangiitis","volume":"158","author":"Laorden","year":"2021","journal-title":"Med Cl\u00edn (Barc)"},{"key":"B15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12890-021-01397-7","article-title":"Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis","volume":"21","author":"Mart\u00ednez-Rivera","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"8S","key":"B16","first-page":"S401","article-title":"Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis With Polyangiitis","volume":"27","author":"Lee","year":"2021","journal-title":"JCR: Journal of Clinical Rheumatology"},{"key":"B17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.alit.2020.03.001","article-title":"Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis","volume":"69","author":"Colantuono","year":"2020","journal-title":"Allergol Int"},{"key":"B18","first-page":"101050","article-title":"Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis","volume":"30","author":"Coppola","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"B19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4081\/mrm.2021.779","article-title":"Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip Respir Med"},{"key":"B20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.alit.2019.04.006","article-title":"Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Takenaka","year":"2019","journal-title":"Allergol Int"},{"key":"B21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.18176\/jiaci.0689","article-title":"Benralizumab: resolution of eosinophilic pulmonary vasculitis in a patient with EGPA","volume":"31","author":"Bormioli","year":"2021","journal-title":"J Investig Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.18176\/jiaci.0648","article-title":"Efficacy of benralizumab and clinical course of IgG4 in eosinophilic granulomatosis with polyangiitis","volume":"31","author":"Miyata","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.jaip.2020.05.033","article-title":"Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis","volume":"8","author":"Padoan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00451-2020","article-title":"Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Nanzer","year":"2020","journal-title":"ERJ Open Res"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"B27","doi-asserted-by":"crossref","first-page":"108574","DOI":"10.1016\/j.clim.2020.108574","article-title":"Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis","volume":"222","author":"Kolios","year":"2021","journal-title":"Clin Immunol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1097\/RHU.0000000000001419","article-title":"Benralizumab as a potential adjunctive therapy in eosinophilic granulomatosis with polyangiitis","volume":"27","author":"Lee","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.jaip.2020.04.006","article-title":"Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab","volume":"8","author":"Ho\u010devar","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B30","doi-asserted-by":"crossref","first-page":"rkab033","DOI":"10.1093\/rap\/rkab033","article-title":"Emergence of extrathoracic manifestations of eosinophilic granulomatosis with polyangiitis during benralizumab treatment","volume":"5","author":"Lim","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"B31","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/rheumatology\/keaa572","article-title":"Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma","volume":"60","author":"Caminati","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2169\/internalmedicine.3606-19","article-title":"Promising effects of benralizumab on chronic eosinophilic pneumonia","volume":"59","author":"Isomoto","year":"2020","journal-title":"Intern Med"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2214\/AJR.16.17315","article-title":"A review of clinical and imaging findings in eosinophilic lung diseases","volume":"208","author":"Bernheim","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/TCRM.S157882","article-title":"Chronic eosinophilic pneumonia: clinical perspectives","volume":"15","author":"Crowe","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"B35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/JAA.S343272","article-title":"Anti-IL-5 agents for the treatment of idiopathic chronic eosinophilic pneumonia: a case series","volume":"15","author":"Tashiro","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.anai.2021.02.016","article-title":"Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab","volume":"126","author":"Ricketti","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"e00810","DOI":"10.1002\/rcr2.810","article-title":"Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection","volume":"9","author":"Takano","year":"2021","journal-title":"Respirol Case Rep"},{"key":"B38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.18176\/jiaci.0671","article-title":"Efficacy of mepolizumab extended interval dosing for 2 asthmatic patients with chronic eosinophilic pneumonia","volume":"31","author":"Sato","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"key":"B40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.alit.2020.07.005","article-title":"Benralizumab as initial treatment for chronic eosinophilic pneumonia","volume":"70","author":"Yazawa","year":"2021","journal-title":"Allergol Int"},{"key":"B41","first-page":"101062","article-title":"Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia","volume":"30","author":"Izumo","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"B42","first-page":"101339","article-title":"A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab","volume":"32","author":"Tsubouchi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"B43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18176\/jiaci.0564","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with benralizumab in a patient who did not respond to omalizumab","volume":"30","author":"Bernal-Rubio","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B44","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jaip.2018.11.024","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with benralizumab","volume":"7","author":"Soeda","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B45","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"B46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/ijmr.IJMR_1187_19","article-title":"Allergic bronchopulmonary aspergillosis","volume":"151","author":"Agarwal","year":"2020","journal-title":"Indian J Med Res"},{"key":"B47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1183\/09031936.00139513","article-title":"Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis","volume":"43","author":"Moss","year":"2014","journal-title":"Eur Respir J"},{"key":"B48","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1378\/chest.14-0917","article-title":"Diagnosis and treatment of pulmonary aspergillosis syndromes","volume":"146","author":"Patterson","year":"2014","journal-title":"Chest"},{"key":"B49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2500\/ar.2015.6.0128","article-title":"Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis","volume":"6","author":"Beam","year":"2015","journal-title":"Allergy Rhinol (Providence)"},{"key":"B50","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2500\/aap.2015.36.3909","article-title":"Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center's experience with 14 cases","volume":"36","author":"Ayd\u0131n","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"B51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2018.12.008","article-title":"Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab","volume":"68","author":"Soeda","year":"2019","journal-title":"Allergol Int"},{"key":"B52","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B53","first-page":"e9684","article-title":"Mepolizumab as possible treatment for allergic bronchopulmonary aspergillosis: a review of eight cases","volume":"12","author":"Tolebeyan","year":"2020","journal-title":"Cureus"},{"key":"B55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/medicina58010053","article-title":"The use of targeted monoclonal antibodies in the treatment of ABPA\u2014a case series","volume":"58","author":"O'Reilly","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B54","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.alit.2020.03.003","article-title":"Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment","volume":"69","author":"Tomomatsu","year":"2020","journal-title":"Allergol Int"},{"key":"B56","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2169\/internalmedicine.6217-20","article-title":"Successful treatment with benralizumab for allergic bronchopulmonary aspergillosis that developed after disastrous heavy rainfall in Western Japan","volume":"60","author":"Matsuura","year":"2021","journal-title":"Intern Med"},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1097\/01.mcp.0000130330.29422.8d","article-title":"Eosinophilic interstitial lung disease","author":"Alberts","year":"2004"},{"key":"B58","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B59","article-title":"Efficacy and safety of benralizumab in EGPA compared to mepolizumab. - full text view - ClinicalTrials.gov [Internet]"},{"key":"B60","article-title":"Benralizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) study - full text view - ClinicalTrials.gov [Internet]"},{"key":"B61","doi-asserted-by":"crossref","first-page":"826790","DOI":"10.3389\/fphar.2021.826790","article-title":"Case report: eosinophilic bronchiolitis with eosinophil ETosis in mucus plugs successfully treated with benralizumab","volume":"12","author":"Sasaki","year":"2022","journal-title":"Front Pharmacol"},{"key":"B62","doi-asserted-by":"crossref","first-page":"e246058","DOI":"10.1136\/bcr-2021-246058","article-title":"Eosinophilic bronchiolitis successfully treated with benralizumab","volume":"14","author":"Sugino","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B63","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.3390\/ijms22137091","article-title":"The enigma of eosinophil degranulation","volume":"22","author":"Fettrelet","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B64","first-page":"1341","article-title":"Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses","volume":"25","author":"Melo","year":"2010","journal-title":"Histol Histopathol"},{"key":"B65","doi-asserted-by":"crossref","first-page":"105819","DOI":"10.1016\/j.rmed.2019.105819","article-title":"Eosinophils, the IL-5\/IL-5R\u03b1 axis, and the biologic effects of benralizumab in severe asthma","volume":"160","author":"Matucci","year":"2019","journal-title":"Respir Med"},{"key":"B66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.alit.2020.10.002","article-title":"How to detect eosinophil ETosis (EETosis) and extracellular traps","volume":"70","author":"Fukuchi","year":"2021","journal-title":"Allergol Int"},{"key":"B67","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1164\/rccm.202012-4374IM","article-title":"Charcot\u2013Leyden crystals in rapidly progressing plastic bronchitis","volume":"204","author":"Ikari","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B68","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2022.03.003","article-title":"Asthma control, airway mucus, and 129Xe MRI ventilation after a single benralizumab dose","author":"McIntosh","year":"2022","journal-title":"Chest"},{"key":"B70","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"B71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10495-016-1226-5","article-title":"Eosinophil resistance to glucocorticoid-induced apoptosis is mediated by the transcription factor NFIL3","volume":"21","author":"Pazdrak","year":"2016","journal-title":"Apoptosis"},{"key":"B72","doi-asserted-by":"crossref","first-page":"106260","DOI":"10.1016\/j.rmed.2020.106260","article-title":"Oral corticosteroid sparing effects of anti-IL5\/anti-IL5 receptor treatment after 2 years of treatment","volume":"176","author":"Bjerrum","year":"2021","journal-title":"Respir Med"},{"key":"B73","doi-asserted-by":"crossref","first-page":"4839230","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"Biomed Res Int"},{"key":"B74","doi-asserted-by":"crossref","first-page":"2004306","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity","volume":"59","author":"Dagher","year":"2022","journal-title":"Eur Respir J"},{"key":"B75","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: a new approach for the treatment of severe eosinophilic asthma","volume":"29","author":"D\u00e1vila Gonz\u00e1lez","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B76","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fmed.2017.00101","article-title":"Homeostatic eosinophils: characteristics and functions","volume":"4","author":"Marichal","year":"2017","journal-title":"Front Med (Lausanne)"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2022\/00000043\/00000006\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T11:39:02Z","timestamp":1675165142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2022.43.220056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11,1]]}},"alternative-id":["1088-5412(20221101)43:6L.494;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2022.43.220056","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}